Longhorn Vaccines and Diagnostics, LLC is at the forefront of developing innovative healthcare solutions aimed at diagnosing, preventing, and treating a wide range of diseases, including viral and bacterial infections as well as inflammatory diseases like Alzheimer’s and Parkinson’s. The company’s flagship product, PrimeStore® Molecular Transport Medium (MTM), is a patented and FDA-cleared device that plays a critical role in the safe collection and transport of biological samples. This technology not only inactivates pathogens but also preserves the integrity of RNA and DNA, making it essential for molecular testing, particularly during public health emergencies such as the COVID-19 pandemic. PrimeStore MTM has also been utilized in managing outbreaks of diseases like H5N1 in livestock, demonstrating its versatility and reliability in both human and animal health contexts.

In addition to its diagnostic capabilities, Longhorn is actively engaged in vaccine development, focusing on broad coverage vaccines to combat antimicrobial resistance and sepsis. The company’s LHNVD-303 vaccine candidate is designed to prevent bacterial infections and sepsis by targeting key components of bacterial cell walls that contribute to inflammation and chronic disease. Longhorn's commitment to One Health principles underscores its approach to addressing zoonotic diseases and ensuring that its products can effectively respond to global health challenges. Through collaborations with research institutions and health organizations, Longhorn aims to enhance public health outcomes and prepare for future pandemics, reinforcing its role as a trusted partner in the healthcare landscape.

United States

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

Longhorn Vaccines and Diagnostics, LLC

Company Details